Chief Technical and Development Officer · Candel Therapeutics, Inc. (CADL)

Seshu Tyagarajan

FY2024 is the first fiscal year CompBrief holds for Seshu Tyagarajan as a named executive officer of Candel Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$613,231

Salary $401,361Stock awards $0

3rd of 3 named executive officers at Candel Therapeutics by FY2024 total.

3 named officers on file for Candel Therapeutics, FY2024

Seshu Tyagarajan’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Candel Therapeutics’s whole pay program stands against its peers

  • Candel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CADL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 1, 1900 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Seshu Tyagarajan’s full pay file as a PDF — free

More than this page: up to 10 years of Seshu’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Seshu Tyagarajan compensation by year

Candel Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Candel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$401,361
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive$198,070
Pension and deferred compensation$0
All other$13,800
Total$613,231

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed January 1, 1900, accession 0000950170-25-060093, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Candel Therapeutics, Inc. filed document, accession 0000950170-25-060093. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU52,258$453,599—
Option40,000—$5.19
Option52,500—$1.29

Per the Outstanding Equity Awards at Fiscal Year-End table in Candel Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

18 Form 4 lines since the FY2024 proxy (filed January 1, 1900)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-17Sale10b5-17,000$12.0076,865
2026-06-29Sale10b5-17,000$10.0283,865
2026-01-26Grant or award derivative—154,000$0.00154,000
2025-06-25Grant or award—5,353$4.6790,865
2025-03-17Exercise or conversion10b5-120,000$1.29116,790
2025-03-17Sale10b5-131,278$8.8285,512
2025-03-17Exercise or conversion derivative10b5-120,000$0.0070,000
2025-03-17Sale10b5-131,278$8.8285,512

The 8 most recent of 18 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Candel Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Paul Peter TakChief Executive Officer$1,449,222
Francesca BaroneChief Scientific Officer$726,222
Seshu Tyagarajan · this pageChief Technical and Development Officer$613,231

The full Candel Therapeutics compensation record

free company brief

This page is one person within Candel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Candel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Seshu Tyagarajan's compensation dossier · One-time report. No refunds.